Virios Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). The company is led by an executive team highly experienced in the successful development of therapies for FM. Its lead candidate, IMC-1, was granted fast track designation by the FDA.